COUR Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Myasthenia Gravis … [Read more...] about COUR Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Myasthenia Gravis
COUR Pharmaceuticals Announces $30M Financing Led by Alpha Wave Ventures … [Read more...] about COUR Pharmaceuticals Announces $30M Financing Led by Alpha Wave Ventures
COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model … [Read more...] about COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model
COUR Pharmaceuticals Appoints Brian C. Bock as Chief Financial Officer … [Read more...] about COUR Pharmaceuticals Appoints Brian C. Bock as Chief Financial Officer
COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis … [Read more...] about COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis
CBRE Arranges Expansion Lease for Cour Pharmaceuticals … [Read more...] about CBRE Arranges Expansion Lease for Cour Pharmaceuticals
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S. … [Read more...] about Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.
COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy … [Read more...] about COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy
